Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Billiontoone, Inc. (NASDAQ:BLLN) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $129.5714.

Several analysts have issued reports on BLLN shares. Stifel Nicolaus began coverage on Billiontoone in a report on Monday, December 1st. They set a “buy” rating and a $145.00 price objective on the stock. Weiss Ratings began coverage on shares of Billiontoone in a report on Tuesday, February 3rd. They issued a “sell (d)” rating for the company. William Blair initiated coverage on shares of Billiontoone in a report on Monday, December 1st. They set an “outperform” rating on the stock. BTIG Research reduced their price target on shares of Billiontoone from $160.00 to $140.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Billiontoone in a research note on Wednesday, December 10th.

Billiontoone Trading Down 2.6%

BLLN opened at $70.20 on Wednesday. The company has a market cap of $3.21 billion and a price-to-earnings ratio of 702.00. The stock’s fifty day moving average is $85.01. Billiontoone has a fifty-two week low of $66.00 and a fifty-two week high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The company had revenue of $96.05 million for the quarter, compared to analyst estimates of $85.85 million. The firm’s revenue was up 113.0% compared to the same quarter last year.

Institutional Trading of Billiontoone

Hedge funds and other institutional investors have recently modified their holdings of the business. Rossby Financial LCC acquired a new position in Billiontoone during the fourth quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in Billiontoone during the 4th quarter worth about $76,000. Smartleaf Asset Management LLC purchased a new position in Billiontoone during the 4th quarter valued at about $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone in the 4th quarter valued at about $82,000. Finally, Renaissance Capital LLC acquired a new position in shares of Billiontoone in the 4th quarter valued at about $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.